TIDES CDMO Services
Porton One-stop Peptide & Oligonucleotide Drug CDMO Service Platform provides comprehensive services for peptide drugs and oligonucleotide drugs, including early-stage research, process development and manufacturing, formulation development and drug product manufacturing, analytical method development and validation, as well as global regulatory affairs support.
100+
Global Customers
~30
IND/NDA Filings
50+
Experienced Scientists
Our Services
Peptides
Linear Peptides
Monocyclic & Multicyclic Peptides
Peptides with Special Sequences and Modified Functionalities
Unnatural Amino Acids and Peptide Fragment Intermediates
Oligonucleotides
ASO, siRNA
PMO
Aptamer
sgRNA
Oligo Modifications
Drug Delivery Materials
Ionizable Lipids / Cationic Lipids
Polymers for Drug Delivery
Other Lipids
Linear Peptides
Monocyclic & Multicyclic Peptides
Peptides with Special Sequences and Modified Functionalities
Unnatural Amino Acids and Peptide Fragment Intermediates
Molecular Type
-
Linear Peptides (< 65 AA)
-
Monocyclic & Multicyclic Peptides with Linkages of
- Disulfides
- Amides
- Thioethers
-
RCM, Click, etc.
-
Peptides with Special Sequences and Modified Functionalities
- Peptides with Multiple Free Cys
- N-alkyl-rich Peptides
- Unnatural Amino Acids and Peptide Fragment Intermediates
- Key RSMs and Intermediates
- ADC Drug-Linker and PDC (OEB 5)
Technology
- Solid/Liquid/Hybrid Strategies Synthetic Solutions
- Combined Downstream Technologies with RP-prep-HPLC, Ionic Exchange, and TFF Technology
- Preformulation Development
- Comprehensive Analysis and Quality Research
Service Scope
- mg-g Scale Sample Preparation for Preclinical Studies
- Process Development and Scale-up Mfg. (non-GMP and GMP)
- Formulation Development and GMP Manufacturing
- Analytical Method Development, Validation, and Stability Study
- IND/NDA CMC Dossier
Service Mode
- FTE (Full-time Equivalent)
- FFS (Fee for Service)
ASO, siRNA
PMO
Aptamer
sgRNA
Oligo Modifications
Molecular Type
- 16-100 mer Oligonucleotides and Derivatives
- Modified Nucleotides
- Oligonucleotide Conjugates
- Custom Monomers
- Custom GalNAc Derivatives
Technology
- Solid Phase Oligonucleotide Synthesis Technology Platform
- Ion Exchange, Ultrafiltration, Freeze-drying, and Other Purification and Post-processing Technologies
- R&D capabilities in nucleic acid modification and routine injectable preparation (including LNP)
- Comprehensive Analysis and Quality Research
Service Scope
- mg-g Scale Sample Preparation for Preclinical Studies
- Process Development and Scale-up Manufacturing (non-GMP and GMP)
- Formulation Development and GMP Manufacturing
- Analytical Method Development, Validation, and Stability Study
- IND/NDA CMC Dossier
Service Mode
- FTE (Full-time Equivalent)
- FFS (Fee for Service)
Ionizable Lipids / Cationic Lipids
Polymers for Drug Delivery
Other Lipids
Molecular Type
- Polymer-drug Conjugates, Dendrimers, Polypeptides
- Cationic/Ionizable Lipids, PEG-lipid, Phospholipids
- GalNAc Derivatives, Modified Monosaccharides, Synthetic Oligosaccharides and Polysaccharides
Technology
- Solid Phase and Liquid Phase Synthesis Technology Platform
- Combined Downstream Technologies with prep-HPLC and Rp-prep-HPLC, Ion Exchange, and TFF Technology
- Formulations Development and Manufacturing
- Comprehensive Analysis, Inspection and Quality Research
Service Scope
- mg-g Scale Sample Preparation for Preclinical Studies
- Process Development and Scale-up Manufacturing. (non-GMP and GMP)
- Analytical Method Development, Validation, and Stability Study
- IND/NDA CMC Dossier
Service Mode
Porton Sites
Minhang, Shanghai
- Area: 22,000 m2
- For mg-kg Scale Preparation, Process Development and Quality Research
- HP Area: Achieved OEB 5 (OEL < 0.05 μg/m3)
Fengxian, Shanghai
- Area: 64,000 m2
- IND, GMP Clinical Batches and Commercial Manufacturing
- HP Area: Achieved OEB 5 (OEL < 0.05 μg/m3)
Liangjiang, Chongqing
- Area: 34,000 m2
- 6 Drug Product GMP Workshops
- Liquid Injection: 30 M units/year
- Lyophilized Powder: 3.3 M units/year
Pudong, Shanghai
- Area: 5,000+ m2
- Bioconjugation (10–200 L, OEB 5)
- Oral, Injectable
- Preclinical to Phase II
Case Studies
More
PMO Therapeutics: Technical Review and Manufacturing Platform Capabilities
This article offers a systematic overview of PMO drug technology covering underlying principles, manufacturing workflows, and therapeutic prospects.
More
Mechanistic Studies in Catalytic Process Development: Supporting Manufacturing Processes and Revealing New Reaction Pathways
Through a case study on loading-dependent chemoselectivity in amide reductions, we demonstrate how first-principles chemical understanding provides the scientific foundation necessary for robust, end-to-end commercial manufacturing control strategies
More
FAQ: Applications of Different Synthetic Strategies for Peptide Process Development
What is the application value, cost characteristics and selection principles of pseudoproline dipeptides in peptide synthesis?
More
Biocatalysis Enables the Efficient Synthesis and Commercial Application of Unnatural Amino Acids (UAAs)
Biocatalysis is a pivotal enabler for the sustainable synthesis of unnatural amino acids. By integrating novel enzyme discovery, multi-enzyme cascades and chemo-enzymatic routes, Porton has established practical capabilities to address industry challenges in substrate specificity and enzyme stability. Moving forward, Porton remains dedicated to bridging the gap between laboratory innovation and industrial-scale application, providing customers with reliable, scalable and atom-efficient solutions for UAA production.
More
Dry Particle Coating for the Enhancement of API Flowability and Bulk Density
The mechanism of the dry particle coating and a short description of four coating techniques including comil, LabRAM, a high shear mixer and a jet mill are provided.
More
The Perfect Integration of Immobilized Enzymes and Flow Chemistry: A Powerful Booster for the Commercialization of Biocatalysis Technology
Adhering to Porton's core value of “Pursuing Excellence”, the Porton biocatalysis team has designated "enzyme immobilization technology and its industrialization" as a core strategic technology.
More
Process Simulation Platform: Enabling Process Development and Scale-up of Active Pharmaceutical Ingredients
The Porton Crystallization team has the capability to perform process simulation of unit operations, including solvent swap, crystallization, filtration and drying.
More
Optimizing Process Chemistry for Enhanced Pharmaceutical Manufacturing
Process Chemistry Optimization | Pharma Manufacturing
More
Expert Q&A: How to Efficiently Apply Preparative Chromatography in Drug Research
How to Efficiently Apply Preparative Chromatography in Drug Research
More
Biocatalysis: A Powerful and Possible Greener Tool for Chemists in the Pharmaceutical Industry
End-to-end Enzyme Solutions
More
Expert Q&A: Molecular Simulation and Data Science Support of Porton
Explore virtual screening duration, differences from property optimization, and crystal structure requirements for impurity rejection calculations.
More
Selecting the Right Solid Form-Faster, Smarter, Better
At Porton J-Star, we employ an integrated approach to identify and select the most suitable solid form for development (Figure 2). We conduct effective screening and rigorous assessments for polymorphs, salts, cocrystals, as well as amorphous solid dispersions, by applying our comprehensive expertise and experience.
More
News
MoreNews2026-09-15
Porton Chongqing Liangjiang Drug Product Manufacturing Site Earns Recertification of ISO 14001 & ISO 45001
More
News2026-09-01
Porton to Showcase End-to-End CDMO Expertise at CPHI Milan 2026
More
News2026-07-02
Porton Highlights Integrated CDMO Capabilities at BIO International Convention 2026 and Celebrates Porton J-STAR's 30th Anniversary
More
News2026-06-25
Porton Concludes Productive Presence at CPHI China 2026
More
News2026-04-03
Porton & Pliant Joint Publication in ACS Catalysis
More
News2026-03-31
Porton Newsletter - March 2026 Recap
More
News2026-03-22
Porton and Jianxiang Forge Strategic Partnership to Build a New High Ground for Large-scale Peptide Drug Manufacturing
More
News2026-03-03
Porton Wins “2025 Best CRO” Award from Daewoong Pharma
More
News2026-02-28
Porton Newsletter - February 2026 Recap
More
News2026-02-03
Porton Newsletter - January 2026 Recap
More
News2026-01-09
Porton Newsletter - Q4 2025 Recap
More
News2026-01-08
A Porton Publication in ACS Journal on Polymorphic Crystallization Kinetics Study and Control
More
